| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 3219 | 2019 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 659 | 2013 |
| Human recombinant activated protein C for severe sepsis AJ Martí‐Carvajal, G Salanti, AF Cardona, AF Cardona‐Zorrilla Cochrane database of systematic reviews, 2007 | 517 | 2007 |
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study S Novello, J Mazières, IJ Oh, J De Castro, MR Migliorino, Å Helland, ... Annals of Oncology 29 (6), 1409-1416, 2018 | 330 | 2018 |
| The coagulant response in sepsis and inflammation M Levi Hämostaseologie 30 (01), 10-16, 2010 | 251 | 2010 |
| Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and … M Chalabi, A Cardona, DR Nagarkar, AD Scala, DR Gandara, A Rittmeyer, ... Annals of Oncology 31 (4), 525-531, 2020 | 242 | 2020 |
| Lung cancer in never smokers: The role of different risk factors other than tobacco smoking L Corrales, R Rosell, AF Cardona, C Martin, ZL Zatarain-Barron, O Arrieta Critical reviews in oncology/hematology 148, 102895, 2020 | 236 | 2020 |
| Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) O Arrieta, AF Cardona, C Martín, L Más-López, L Corrales-Rodríguez, ... Journal of Thoracic Oncology 10 (5), 838-843, 2015 | 211 | 2015 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 178 | 2023 |
| Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor–mutated lung adenocarcinoma … O Arrieta, F Barrón, MÁS Padilla, A Avilés-Salas, LA Ramírez-Tirado, ... JAMA oncology 5 (11), e192553-e192553, 2019 | 163 | 2019 |
| Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ... JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017 | 162 | 2017 |
| Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non–small cell lung cancer MA Molina-Vila, J Bertran-Alamillo, A Gascó, C Mayo-de-las-Casas, ... Clinical Cancer Research 20 (17), 4647-4659, 2014 | 158 | 2014 |
| Antibiotics for acute laryngitis in adults L Reveiz, AF Cardona Cochrane Database of Systematic Reviews, 2015 | 150 | 2015 |
| The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial JG Turcott, M del Rocío Guillen Núñez, D Flores-Estrada, ... Supportive Care in Cancer 26, 3029-3038, 2018 | 145 | 2018 |
| Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: The PROLUNG phase 2 randomized … O Arrieta, F Barrón, LA Ramírez-Tirado, ZL Zatarain-Barrón, AF Cardona, ... JAMA oncology 6 (6), 856-864, 2020 | 143 | 2020 |
| Genotyping non-small cell lung cancer (NSCLC) in Latin America O Arrieta, AF Cardona, GF Bramuglia, A Gallo, AD Campos-Parra, ... Journal of Thoracic Oncology 6 (11), 1955-1959, 2011 | 138 | 2011 |
| EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins J Remon, LEL Hendriks, AF Cardona, B Besse Cancer treatment reviews 90, 102105, 2020 | 137 | 2020 |
| Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer YL Wu, R Dziadziuszko, JS Ahn, F Barlesi, M Nishio, DH Lee, JS Lee, ... New England Journal of Medicine 390 (14), 1265-1276, 2024 | 131 | 2024 |
| Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations J Carrot-Zhang, G Soca-Chafre, N Patterson, AR Thorner, A Nag, ... Cancer discovery 11 (3), 591-598, 2021 | 126 | 2021 |
| AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy J Bertran-Alamillo, V Cattan, M Schoumacher, J Codony-Servat, ... Nature communications 10 (1), 1812, 2019 | 116 | 2019 |
